We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Parker Laboratories Introduces Groundbreaking Ultrasound Innovations

By HospiMedica International staff writers
Posted on 13 Nov 2023
Image: Tristel ULT is a high-level disinfectant foam to disinfect cleaned, reusable, non-lumened ultrasound probes (Photo courtesy of Parker Labs)
Image: Tristel ULT is a high-level disinfectant foam to disinfect cleaned, reusable, non-lumened ultrasound probes (Photo courtesy of Parker Labs)

Parker Laboratories Inc. (Fairfield, NJ, USA) is introducing innovative ultrasound products at MEDICA 2023 that are designed to increase patient safety, lower costs, and improve workflow in busy healthcare settings that rely on point-of-care ultrasound. The company is introducing the UltraDrape II UGPIV Barrier and Securement Dressing and Tristel ULT high-level disinfectant foam that promotes patient safety while reducing costs and increasing efficiency for ultrasound-guided percutaneous procedures.

Ultrasound technologies offer important advantages for vascular access procedures such as inserting central lines and peripheral catheters, improving outcomes while also reducing risks and healthcare costs. Hospitals are seeing an increase in the number of patients with difficult vascular access (DiVA) who require ultrasound guidance to achieve peripheral vascular access. UltraDrape II is the next generation of Parker’s groundbreaking UltraDrape, the only dressing designed specifically for use during UGPIV procedures. Like the original, UltraDrape II is a sterile, dual-action barrier and securement dressing that provides a “gel-free” insertion site to decrease the risk of contamination and securement failure both during and after UGPIV procedures.

Tristel ULT is a high-level disinfectant that uses unique, proprietary foam containing chlorine dioxide for reprocessing ultrasound probes. It was recently granted FDA clearance for use as a high-level disinfectant for ultrasound probes used within body cavities and for skin-surface transducers, making it the first product of its kind to be available in the United States. Tristel ULT is the only high-level disinfectant foam that can be safely used on ultrasound probes, and it has been shown to be effective against pathogens ranging from SARS-CoV-2 to Mycobacterium tuberculosis. As a rapid and inexpensive high-level disinfectant, Tristel ULT represents an important advance offering several advantages over other methods of high-level disinfection currently on the market.

“As the use of ultrasound guidance for vascular access procedures increases, so does the need for supplies that make these procedures safer and more efficient, without increasing costs,” said Neal Buchalter, president of Parker Laboratories. “These new products are just a few of the innovative and cost-effective solutions we are committed to bring to market to increase patient safety and improve workflow for busy vascular access clinicians.”

Related Links:
Parker Laboratories Inc.

Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Monitor/Defibrillator
Zenix
Medical Adhesive
MED 5570U

Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Medica 2023